New immunotherapy combo aims to control lung cancer after standard treatment
NCT ID NCT07381543
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding the immunotherapy drug adebrelimab to standard chemoradiotherapy, followed by maintenance adebrelimab, can help control limited-stage small cell lung cancer. About 76 adults aged 18-75 with untreated localized disease will be enrolled. The study compares two groups: one receiving adebrelimab plus chemo-radiation, and another receiving chemo-radiation alone, with all participants then getting adebrelimab maintenance. The main goal is to see if the combination delays cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adebrelimab (an immunotherapy drug) combined with chemotherapy and radiation
- What this could lead to
- If successful, this could offer a new maintenance treatment option to help control limited-stage small cell lung cancer and delay progression.
- What could go wrong
- This is an early Phase 2 trial with only 76 participants, so results may not apply broadly. Immunotherapy can cause immune-related side effects, and the treatment may not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALIZED SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Cancer Hospital and Institute
Beijing, Beijing Municipality, 100142, China